Glenmark Pharma

Has Glenmark Pharma declared dividend?

Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly in the long term.

Glenmark Pharmaceuticals Ltd. has declared a 250% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 3.97%, with no dividend return, resulting in a total return of 3.97%.<BR><BR>Over the past year, the price return was 31.68%, with a dividend return of 0.21%, leading to a total return of 31.89%.<BR><BR>In the 2-year period, the price return was 152.58%, with a dividend return of 0.78%, culminating in a total return of 153.36%.<BR><BR>For the 3-year period, the price return was 305.84%, with a dividend return of 2.04%, resulting in a total return of 307.88%.<BR><BR>In the last 4 years, the price return was 159.41%, with a dividend return of 1.50%, giving a total return of 160.91%.<BR><BR>Over the 5-year period, the price return was 295.81%, with a dividend return of 2.87%, leading to a total return of 298.68%.<BR><BR>Overall, Glenmark Pharma has declared a substantial dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting a positive performance trend for the company.

Who are the peers of the Glenmark Pharma?

Glenmark Pharma's peers include Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Biocon, and Laurus Labs. Glenmark has an average management risk and a 1-year return of 56.34%, outperforming Zydus Lifesci. but lower than Laurus Labs' 76.44%.

Peers: Glenmark Pharma's peers are Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Biocon, Laurus Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Reddy's Labs, Abbott India, and Glaxosmi. Pharma, while Good management risk is found at Zydus Lifesci., Aurobindo Pharma, Alkem Lab, and Laurus Labs. Average management risk is present at Lupin, Glenmark Pharma, and Biocon. In terms of Growth, Excellent growth is seen at Dr Reddy's Labs and Zydus Lifesci., while Average growth is noted at Abbott India and Laurus Labs, and Below Average growth is found at Aurobindo Pharma, Glenmark Pharma, Alkem Lab, Glaxosmi. Pharma, and Biocon. For Capital Structure, Excellent capital structure is observed at Dr Reddy's Labs, Zydus Lifesci., Abbott India, Aurobindo Pharma, and Glaxosmi. Pharma, while Good capital structure is present at Glenmark Pharma, and Average capital structure is seen at Laurus Labs and Biocon.<BR><BR>Return Snapshot: Glenmark Pharma has a 1-year return of 56.34%, while the highest return is from Laurus Labs at 76.44% and the lowest is from Zydus Lifesci. at -18.37%. Glenmark Pharma's return is significantly higher than Zydus Lifesci.'s. Additionally, Aurobindo Pharma and Alkem Lab have negative six-month returns.

Who are in the management team of Glenmark Pharma?

As of March 2023, Glenmark Pharma's management team includes Glenn Saldanha (Chairman/Executive Director), Cheryl Pinto (Executive Director), and several independent directors, totaling a diverse group focused on governance and strategic direction.

As of March 2023, the management team of Glenmark Pharma includes:<BR><BR>1. Glenn Saldanha - Chairman / Executive Director<BR>2. Cheryl Pinto - Executive Director (Corporate)<BR>3. V S Mani - Executive Director & Group CFO<BR>4. B E Saldanha - Non Executive Director<BR>5. Rajesh Desai - Independent Non Executive Director<BR>6. Devendra Raj Mehta - Independent Non Executive Director<BR>7. Bernard Munos - Independent Non Executive Director<BR>8. Brian W Tempest - Independent Non Executive Director<BR>9. Sridhar Gorthi - Independent Non Executive Director<BR>10. Sona Saira Ramasastry - Independent Non Executive Director<BR>11. Dipankar Bhattacharjee - Independent Non Executive Director<BR>12. V R Iyer - Independent Non Executive Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What does Glenmark Pharma do?

Glenmark Pharmaceuticals Ltd. is a large-cap company engaged in the discovery, development, manufacture, and marketing of pharmaceutical products. As of March 2025, it reported net sales of ₹32,562 Cr and a net profit of ₹46 Cr, with a market cap of ₹62,822 Cr.

Overview: <BR>Glenmark Pharmaceuticals Ltd. is a large-cap company in the Pharmaceuticals & Biotechnology industry, focused on the discovery, development, manufacture, and marketing of pharmaceutical products, including both formulations and active pharmaceutical ingredients.<BR><BR>History: <BR>Glenmark Pharmaceuticals Ltd. was incorporated on November 18th, 1977. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 32,562 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 46 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 62,822 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 50.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.11% <BR>Debt Equity: 0.09 <BR>Return on Equity: 14.15% <BR>Price to Book: 7.11<BR><BR>Contact Details: <BR>Address: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road Mumbai Maharashtra : 400026 <BR>Tel: 91-22-40189999 <BR>Email: complianceofficer@glenmarkpharma.co <BR>Website: http://www.glenmarkpharma.com

Who are the top shareholders of the Glenmark Pharma?

The top shareholders of Glenmark Pharma include the Saldanha Family Trust with 45.45%, institutional investors holding 36.02% (including 25 mutual fund schemes at 12.86% and 347 FIIs at 23.16%), and individual investors with 12.32%. HDFC Mutual Fund is the largest public shareholder with a 4.27% stake.

The top shareholders of Glenmark Pharma include the Saldanha Family Trust, which holds the largest stake at 45.45%. The company also has significant institutional backing, with 25 mutual fund schemes collectively holding 12.86% and 347 foreign institutional investors (FIIs) holding 23.16%. Additionally, HDFC Mutual Fund, specifically through the HDFC Nifty Large Midcap 250 Index fund, is the highest public shareholder with a 4.27% stake. Individual investors collectively own 12.32% of the company.

How big is Glenmark Pharma?

As of 24th July, Glenmark Pharmaceuticals Ltd. has a market capitalization of 60,195.00 Cr, with recent net sales of 13,321.73 Cr and a net profit of 1,047.09 Cr.

As of 24th July, Glenmark Pharmaceuticals Ltd. has a market capitalization of 60,195.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Glenmark Pharmaceuticals reported Net Sales of 13,321.73 Cr and a Net Profit of 1,047.09 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 7,847.93 Cr and Total Assets of 13,308.90 Cr.

Is Glenmark Pharma technically bullish or bearish?

As of September 10, 2025, Glenmark Pharma's trend is mildly bullish, supported by daily moving averages and weekly Bollinger Bands, but tempered by mixed signals from the MACD and OBV.

As of 10 September 2025, the technical trend for Glenmark Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum and the weekly Bollinger Bands also showing bullish signals. However, the weekly MACD is mildly bearish and the KST is bullish on a weekly basis but mildly bearish on a monthly basis, suggesting some mixed signals. The Dow Theory indicates a mildly bullish stance on the weekly chart, while the OBV shows a mildly bearish trend. Overall, the strength of the bullish sentiment is tempered by the mixed indicators, particularly on the weekly timeframe.

How has been the historical performance of Glenmark Pharma?

Glenmark Pharma's historical performance shows significant fluctuations, with net sales increasing to 13,321.74 Cr in Mar'25 after a dip in Mar'23, and a recovery in profit after tax to 1,047.14 Cr in Mar'25 from a loss of 1,830.85 Cr in the previous year. Despite negative cash flow from operating activities in Mar'25, the company demonstrates a recovery trajectory following a challenging period.

Answer:<BR>The historical performance of Glenmark Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Glenmark Pharma's net sales increased from 10,640.97 Cr in Mar'20 to 13,321.74 Cr in Mar'25, with a notable dip in Mar'23 at 12,990.11 Cr. Total operating income followed a similar trend, reaching 13,321.74 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 8,279.66 Cr in Mar'19 to 10,970.36 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 2,595.16 Cr in Mar'23 before declining to 2,465.10 Cr in Mar'25. Profit before tax was 1,399.21 Cr in Mar'25, recovering from a low of 36.50 Cr in Mar'24. The profit after tax turned positive at 1,047.14 Cr in Mar'25 after a significant loss of 1,830.85 Cr in the previous year. The earnings per share (EPS) rebounded to 37.1 in Mar'25 from a negative EPS of -53.21 in Mar'24. Total assets increased to 14,925.44 Cr in Mar'25, while total liabilities also rose to 14,925.44 Cr, indicating a balanced growth in the company’s financial structure. Cash flow from operating activities was negative at -827.00 Cr in Mar'25, contrasting with a positive cash flow of 782.00 Cr in Mar'24. Overall, Glenmark Pharma's financial performance reflects a recovery trajectory in 2025 after a challenging previous year.

Is Glenmark Pharma overvalued or undervalued?

As of November 17, 2025, Glenmark Pharma is considered undervalued with a PE ratio of 23.47 and strong growth potential, outperforming peers like Sun Pharma and Cipla, and has delivered a 21.44% return over the past year compared to the Sensex's 9.50%.

As of 17 November 2025, Glenmark Pharma's valuation grade has moved from expensive to attractive, indicating a shift in market perception. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 23.47, an EV to EBITDA of 12.50, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Glenmark Pharma's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 36.69, while Cipla, another attractive peer, has a PE of 22.81. This positions Glenmark favorably within the industry, particularly given its robust ROCE of 44.14% and ROE of 23.46%. Additionally, Glenmark's stock has outperformed the Sensex over the past year, with a return of 21.44% compared to the Sensex's 9.50%, reinforcing the attractiveness of its current valuation.

When is the next results date for Glenmark Pharmaceuticals Ltd.?

The next results date for Glenmark Pharmaceuticals Ltd. is January 30, 2026.

The next results date for Glenmark Pharmaceuticals Ltd. is scheduled for January 30, 2026.

Are Glenmark Pharmaceuticals Ltd. latest results good or bad?

Glenmark Pharmaceuticals Ltd.'s latest results show strong year-on-year growth with a 15.15% increase in net sales and a 15.88% rise in net profit, but significant sequential declines of 35.49% in sales and 33.94% in profit raise concerns about sustainability. Investors should consider these fluctuations in the context of previous quarter's exceptional performance.

Glenmark Pharmaceuticals Ltd.'s latest results present a mixed picture. For the December 2025 quarter (Q3 FY26), the company reported net sales of ₹3,900.62 crores, which reflects a solid year-on-year growth of 15.15%. However, this figure represents a significant sequential decline of 35.49% from the previous quarter, where sales were unusually high due to a one-off spike.<BR><BR>Net profit for the quarter was ₹403.21 crores, marking a 15.88% increase year-on-year but a notable decrease of 33.94% compared to the prior quarter. The operating margin, excluding other income, was 22.37%, which is an improvement from 18.18% in the same quarter last year, but down from an exceptional 39.30% in Q2 FY26.<BR><BR>Overall, while Glenmark has shown strong year-on-year growth and improved operational efficiency, the sequential declines raise concerns about the sustainability of its recent performance. Investors should consider these fluctuations and the context of the previous quarter's extraordinary results when evaluating the company's current standing.

Should I buy, sell or hold Glenmark Pharmaceuticals Ltd.?

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

As of 01-Feb, Glenmark Pharmaceuticals Ltd. is facing a stock price decline to 1,939.40, down 3.84%, and has underperformed its sector today. Despite a year-over-year increase of 33.83%, recent trends indicate short-term market pressures and a lack of buying interest at higher price levels.

As of 01-Feb, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 1,939.40, which reflects a change of -77.5 (-3.84%). This drop is evident as the stock has underperformed its sector by 3.37% today and has touched an intraday low of Rs 1928.85, marking a decrease of 4.37%. <BR><BR>Over the past week, the stock has decreased by 1.59%, and in the last month, it has fallen by 4.44%. Year-to-date, the stock is down 4.74%, although it has shown a significant increase of 33.83% over the past year. Despite this long-term growth, the recent performance indicates a troubling trend, particularly as it is trading lower than the 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average.<BR><BR>The weighted average price suggests that more volume has been traded closer to the low price, indicating a lack of buying interest at higher levels. However, there has been a rise in investor participation, with delivery volume increasing by 4.91% against the 5-day average, which could suggest some underlying interest despite the current price decline.<BR><BR>Overall, while Glenmark Pharmaceuticals Ltd. has strong fundamentals, including a low Debt to EBITDA ratio and impressive profit growth, the recent stock price movement reflects short-term market pressures and a broader trend of underperformance relative to its sector.

Which are the latest news on Glenmark Pharma?